The association of CGG repeats in the FMR1 gene and timing of natural menopause.

STUDY QUESTION Is there an association between the number of CGG repeats in the FMR1 gene in the normal and intermediate range and age at natural menopause? SUMMARY ANSWER The number of CGG repeats in the normal and intermediate range in the FMR1 gene was not associated with age at natural menopause. WHAT IS KNOWN ALREADY Excessive triple CGG repeats in the FMR1 gene have been widely associated with primary ovarian insufficiency. Recently, the number of CGG repeats in the normal and intermediate range (up to 55 repeats) was found to be associated with serum levels of anti-Müllerian hormone and follicle-stimulating hormone, as markers for ovarian ageing. This suggests that repeats in the normal and intermediate range could be involved in the rate of exhaustion of the ovarian primordial follicle pool and ultimately the timing of menopause. STUDY DESIGN, SIZE Cross-sectional study in a population-based sample of 3611 Caucasian women with natural menopause. PARTICIPANTS/MATERIALS, SETTING, METHODS The FMR1 CGG repeat number was determined by PCR amplification in 3611 women with a known age at natural menopause. A possible relation between CGG repeats in the normal and intermediate range (up to 55 repeats) and menopausal age were analysed in various ways, including linear regression analysis and analysis of variance. MAIN RESULTS AND THE ROLE OF CHANCE The number of CGG repeats in the normal and intermediate range in the FMR1 gene was not associated with age at natural menopause. The mean age at menopause was 50.30 (± 4.2) years for women with <45 repeats and 50.64 (± 3.4) years for women with intermediate-sized repeats (P = 0.37). Linear regression analysis of the number of CGG repeats showed no association with menopausal age (β = 0.019, P = 0.16). LIMITATIONS, REASONS FOR CAUTION In our cohort, age at menopause was self-reported and determined retrospectively. WIDER IMPLICATIONS OF THE FINDINGS Earlier observations suggesting that the number of CGG repeats in the normal and intermediate range is associated with the individual variation of the ovarian ageing process could not be confirmed in the current, large sample size study. A relation between the number of CGG repeats in the normal and intermediate range and age at natural menopause appeared to be absent. This finding questions the role of CGG repeat sizes in the ovarian ageing process.

[1]  D. Barad,et al.  Differences in ovarian aging patterns between races are associated with ovarian genotypes and sub-genotypes of the FMR1 gene , 2012, Reproductive Biology and Endocrinology.

[2]  J. Llácer,et al.  Intermediate and normal sized CGG repeat on the FMR1 gene does not negatively affect donor ovarian response. , 2012, Human reproduction.

[3]  T. Ogata,et al.  Number of CGG repeats in the FMR1 gene of Japanese patients with primary ovarian insufficiency. , 2011, Fertility and sterility.

[4]  C. Racowsky,et al.  Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. , 2011, Human reproduction.

[5]  M. Solaymani-Dodaran,et al.  Predicting age at menopause from serum antimüllerian hormone concentration , 2011, Menopause.

[6]  M. Eijkemans,et al.  Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. , 2011, The Journal of clinical endocrinology and metabolism.

[7]  D. Barad,et al.  Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. , 2010, Reproductive biomedicine online.

[8]  P. Jacobs,et al.  Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. , 2010, Human reproduction.

[9]  D. Barad,et al.  Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile women and egg donors. , 2010, Reproductive biomedicine online.

[10]  D. Barad,et al.  A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. , 2009, Fertility and sterility.

[11]  E. Spector,et al.  Clinical significance of tri-nucleotide repeats in Fragile X testing: A clarification of American College of Medical Genetics guidelines , 2008, Genetics in Medicine.

[12]  F. Broekmans,et al.  Relationship of serum antimüllerian hormone concentration to age at menopause. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  M. Epstein,et al.  Examination of reproductive aging milestones among women who carry the FMR1 premutation. , 2007, Human reproduction.

[14]  S. Bione,et al.  Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. , 2006, Human reproduction.

[15]  A. Murray,et al.  Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers , 2006, European Journal of Human Genetics.

[16]  W. Robinson,et al.  FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure , 2005, Human Genetics.

[17]  C. Björkelund,et al.  Reproducibility of self-reported menopause age at the 24-year follow-up of a population study of women in Göteborg, Sweden , 2005, Menopause.

[18]  M. Epstein,et al.  Association of FMR1 repeat size with ovarian dysfunction. , 2005, Human reproduction.

[19]  F. Broekmans,et al.  Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition , 2004, Menopause.

[20]  F. V. van Leeuwen,et al.  Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. , 2003, Human reproduction.

[21]  W. Brown,et al.  Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. , 2003, American journal of human genetics.

[22]  S. Sherman,et al.  Premature ovarian failure in the fragile X syndrome. , 2000, American journal of medical genetics.

[23]  N. Morton,et al.  Reproductive and menstrual history of females with fragile X expansions , 2000, European Journal of Human Genetics.

[24]  W. Brown,et al.  Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. , 1999, American journal of medical genetics.

[25]  E. Eaker,et al.  Reliability of reported age at menopause. , 1997, American journal of epidemiology.

[26]  I. D. Tonkelaar,et al.  Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project , 1997 .

[27]  S. Chatterjee,et al.  CGG repeat sizing in the FMR1 gene in Indian women with premature ovarian failure. , 2009, Reproductive biomedicine online.

[28]  D. Barad,et al.  Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. , 2009, Reproductive biomedicine online.

[29]  E. Riboli,et al.  Prospect-EPIC Utrecht: Study design and characteristics of the cohort population , 2004, European Journal of Epidemiology.

[30]  Paul Brazzell,et al.  Conflict of interest. , 2002, The Canadian veterinary journal = La revue veterinaire canadienne.

[31]  I. den Tonkelaar.  Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. , 1997, Maturitas.